KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Accounts Payables (2020 - 2025)

AbCellera Biologics' Accounts Payables history spans 6 years, with the latest figure at $53.1 million for Q3 2025.

  • For the quarter ending Q3 2025, Accounts Payables fell 1.22% year-over-year to $53.1 million, compared with a TTM value of $53.1 million through Sep 2025, down 1.22%, and an annual FY2024 reading of $55.0 million, up 10.94% over the prior year.
  • Accounts Payables for Q3 2025 was $53.1 million at AbCellera Biologics, up from $50.1 million in the prior quarter.
  • The five-year high for Accounts Payables was $55.0 million in Q4 2024, with the low at $13.3 million in Q1 2021.
  • Average Accounts Payables over 5 years is $38.5 million, with a median of $42.9 million recorded in 2024.
  • Year-over-year, Accounts Payables surged 114.82% in 2023 and then fell 16.11% in 2024.
  • Tracing ABCL's Accounts Payables over 5 years: stood at $32.0 million in 2021, then soared by 63.97% to $52.5 million in 2022, then decreased by 5.56% to $49.6 million in 2023, then grew by 10.94% to $55.0 million in 2024, then decreased by 3.43% to $53.1 million in 2025.
  • Per Business Quant, the three most recent readings for ABCL's Accounts Payables are $53.1 million (Q3 2025), $50.1 million (Q2 2025), and $47.8 million (Q1 2025).